Kaufman Assessment Battery for Children

Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs

Retrieved on: 
Monday, April 3, 2023
HD, SIGNAL, Kaufman Assessment Battery for Children, Neoplasm, Neurodegenerative disease, Pathology, Cancer, Head, Brain, Nature Medicine, Immunotherapy, Merck & Co., Patient, CPS, Observation, AD, SEMA4D, Neurology, PD-L1, Atrophy, Pharmaceutical industry

ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D today announced financial results for the fourth quarter ended December 31, 2022 and provided a corporate update on key programs.

Key Points: 
  • In 2022 and continuing in Q1 2023, Vaccinex has made important clinical progress in its major neurology and oncology programs.
  • We are exploring partnering/financing opportunities for a pivotal phase 3 study in HD while we continue our ongoing high priority SIGNAL-AD study in Alzheimer’s disease.
  • SRF114 is the first clinical candidate to be selected employing the ActivMAb platform and initiation of this clinical study triggered a milestone payment.
  • Financial Results for the Year Ended December 31, 2022:
    Cash and Cash Equivalents and Marketable Securities.

Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

Retrieved on: 
Monday, August 8, 2022
People, U.S. Securities and Exchange Commission, Respiration (physiology), GLOBE, Caudate nucleus, SEC, Cancer, Brain, Behavior, Security (finance), Research, HD, Journal of Neuroinflammation, Diffuse axonal injury, Patient, Tumor microenvironment, Astrocyte, Neurodegeneration, Nature Medicine, Microfilament, Immunosuppression, Health, Disease, Government budget balance, HIV disease progression rates, Inflammation, Neuron, Immunoglobulin G, SEMA4D, Kaufman Assessment Battery for Children, Key finding attacks, Apathy, Nasdaq, Locomotion, Forward-looking statement, Microglia, SIGNAL, Caregiver, Neoplasm, Cell, COVID-19, Program, Mutation, Dementia, Atrophy, Cognition, B cell, FDG-PET, Company, Problem solving, Pharmaceutical industry, Medical imaging, Vaccine, Risk management, Journal

ROCHESTER, N.Y., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced that results of its Phase 2 SIGNAL study to evaluate its SEMA4D-blocking antibody, pepinemab, in patients with Huntington’s Disease (HD) were published in the August 8, 2022 issue of Nature Medicine1, a leading journal for publication of translational and clinical research. In parallel, a second report has been published in the Journal of Neuroinflammation2 detailing the pathologic impact of SEMA4D on neuroinflammatory cells in both HD and Alzheimer’s disease (AD).

Key Points: 
  • These findings encourage continued development of pepinemab as a potential therapy for patients with early manifest symptoms of HD and potentially AD.
  • Accordingly, a phase 1b/2a study of pepinemab in Alzheimers disease has been initiated and is actively enrolling patients (NCT04381468).
  • The mechanism of action of pepinemab, targeting neuroinflammation2, may provide an alternative to other AD therapies that target aggregates of A amyloid.
  • The Nature Medicine publication is available online at https://www.nature.com/articles/s41591-022-01919-8 and Journal of Neuroinflammation at https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-022... ; both articles will also be posted on the Vaccinex website.